Venus Medtech Hangzhou Inc
HKEX:2500

Watchlist Manager
Venus Medtech Hangzhou Inc Logo
Venus Medtech Hangzhou Inc
HKEX:2500
Watchlist
Price: 2.43 HKD 3.4% Market Closed
Market Cap: HK$1.1B

Venus Medtech Hangzhou Inc
Investor Relations

Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2019-12-10. The firm's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and TriGUARD3 Cerebral Embolic Protection Device.

Show more
Loading
2500
Hang Seng (Hong Kong)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Hou-Sen Lim MEng.
GM, COO & CTO
No Bio Available
Mr. Fei Wang
Chief Financial Officer
No Bio Available
Joyce Heo
Director of Sales
No Bio Available
Mr. Christopher Lee Richardson
Head of U.S. Operations
No Bio Available
Mr. Amir Gross
Head of Venus Global Heart Valve Innovation Center
No Bio Available
Shakeel Osman
Senior Vice President of Sales Europe
No Bio Available
Mr. Liqiao Ma
Executive Director
No Bio Available
Mr. Wai Chiu Wong FCS
Company Secretary
No Bio Available

Contacts

Address
ZHEJIANG
Hangzhou
Room 311, 3/F, Block 2, No. 88, Jiangling Road, Binjiang District
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett